VBI Vaccines has launched the PreHevbri [hepatitis B vaccine (recombinant, adsorbed)] for adults in the UK.

The vaccine is intended for active immunisation against all known hepatitis B virus (HBV) subtypes in adults.

PreHevbri is marketed in the UK through the existing commercial infrastructure and distribution networks of Valneva as part of a marketing and distribution agreement signed in September 2022.

The vaccine is also anticipated to prevent hepatitis D, which cannot develop without a hepatitis B infection.

VBI president and CEO Jeff Baxter stated: “We are delighted to announce the availability of PreHevbri in the UK, marking the first European market launch of our 3-antigen hepatitis B vaccine, which builds upon the increasing momentum for use in the US.

“We believe Valneva’s local commercial capabilities and relationships will be of significant value not only in this initial European launch, but also in the additional European markets where PreHevbri is expected to launch over the next several months.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

PreHevbri includes three hepatitis B surface antigens of the virus – S, pre-S1 and pre-S2.

The vaccine also secured approval in the US, Canada, Israel and the European Union/European Economic Area.

It is marketed as PreHevbrio in the US and Canada and as Sci-B-Vac in Israel.

Hepatitis B is a major infectious disease with over 290 million people infected across the world.